The cross-fire never ceases among members of the litigation industry. Nathan Schactman recently posted an interesting new attack on the plaintiff’s bar, tied mainly to the FDA and federal pre-emption issues.

That said, commentary from all sides should taken with several grains of salt – the full story is seldom aired, by either side.